Curium, PeptiDream, PDRadiopharma Launch Prostate Cancer Trial in Japan

Curium, PeptiDream Inc. & PDRadiopharma Inc. Launch Registrational Trial in Japan    👏first patient enrolled in a Phase 2 registrational trial of 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting prostate cancer.

🚀 Breakthrough in HER2⁺ Metastatic Breast Cancer: TUKYSA + Standard Maintenance Shows Promise. Pfizer today announced topline positive results from its Phase 3 HER2CLIMB-05 trial: combining TUKYSA (tucatinib) with trastuzumab + pertuzumab as maintenance therapy significantly improved progression-free survival (PFS) versus placebo, following induction therapy in HER2+ metastatic breast cancer. Pfizer plans to present full data at an upcoming medical congress #Oncology #BreastCancer #HER2 #ClinicalTrials #PharmaInnovation #Pfizer #Tucatinib

Our review article titled “A Comprehensive Review on Advancements in Nanocarriers-Based Peptide Delivery for Cancer Therapeutics” has been published in the journal Micro and Nanosystems. This comprehensive review highlights the latest developments in nanocarrier systems for effective and targeted peptide-based cancer therapy an emerging area with tremendous therapeutic potential. Read the full article here: https://lnkd.in/gV8zy8_N DOI: 10.2174/0118764029358553250325040749 #Research #Nanotechnology #CancerTherapeutics #DrugDelivery #PeptideDelivery #MicroAndNanosystems #ScientificPublication

Radiopharmaceutical therapy is gaining prominence in prostate cancer care, and it’s a key focus at ESMO 2025 (ESMO - European Society for Medical Oncology). UCLA Health's Jeremie Calais, MD, PhD, describes the field as “a hot topic now,” with growing anticipation around new data — particularly from the PSMAddition trial. This study may influence treatment pathways for metastatic hormone-sensitive prostate cancer. Full interview: https://bit.ly/4osxVjG #ESMO25

From pan-KRAS inhibitors to G12D-targeting therapies, the next generation of treatments promises to tackle the complexities of KRAS-driven cancers more effectively, with less resistance and fewer side effects. What does this mean for oncologists?  More options, fewer barriers and the potential for chemotherapy-free regimens. As the KRAS space heats up, oncology leaders have a rare opportunity to redefine cancer treatment strategies. Want to learn more? Click here to dive into the future of KRAS inhibitors and their impact on the oncology landscape: https://lnkd.in/ewcwYMsB #KRAS #PrecisionMedicine #Biotech #CancerTreatment

Targeting KRAS is shifting from speed to strategy. Long-term differentiation will define the winners. Prescient’s new whitepaper unpacks what that means for the next wave of treatments ⤵️

The momentum in IO is undeniable, but the evolution of KRAS-targeting assets is the newest frontier. We just published a whitepaper that looks past the G12C success and focuses on the strategic shift towards new modalities like TPDs and C&GT. If you're in investment or clinical strategy, understanding this shift is crucial. Read the full outlook! 👇 #Biopharma #KRAS #OncologyResearch #Whitepaper

⚛️ Radioligand therapeutics: Latest data & future directions At #ESMO25, two sessions to learn about one of the last frontiers in oncology: Proffered Papers ✔ Targeted alpha therapy in GEP-NETs ✔ 177Lu-PSMA-617 vs docetaxel in mCRPC ✔ Neoadjuvant 177Lu-PSMA therapy in oligometastatic prostate cancer 📅 18 Oct | 16:30–18:00 | Cologne Auditorium – CityCube A Special Session ✔ Imaging-based theranostics: Is this really happening? ✔ What’s next after PSMA & lutetium trials? ✔ Scaling up capacity for radioligand therapy 📅 19 Oct | 12:00–12:50 | Bonn Auditorium – Hall 7.1c 🔗 https://ow.ly/tXbB50XaEV8

Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer https://lnkd.in/g8Fn79dQ AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a peer-reviewed manuscript in the Journal of Clinical Oncology – Precision Oncology (JCO PO). The [...]

We started the development of 64Cu-PSMA-I&T for advanced prostate cancer as part of a registrational trial in Japan. In parallel, we are also planning to start a clinical trial for its therapeutic pair, 117Lu-PSMA-I&T. In collaboration with Curium, PeptiDream and PDRadiopharma are committed to delivering innovative radiopharmaceuticals to patients in Japan, contributing to the future of precision oncology. [👉]  https://lnkd.in/gsY_Mkvf #radiopharmaceutical #PSMA #prostate cancer #theranostics #radioligand therapy #NuclearMedicine